Welcome to: Rimonabant Information Source (rimonabant buy cheap)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

Acomplia (rimonabant) is a pill to reduce obesity. Acomplia rimonabant is an anti-obesity oral prescription drug with rimonabant as its main component. Rimonabant Acomplia is one of the first kind of therapeutic agents known as CB1. Rimonabant is sold in the United Kingdom and the EU under the brand name Acomplia in the United States under the brand name Acomplia. Acomplia rimonabant is manufactured by the world famous French pharmaceutical Sanofi-Aventis. Acomplia rimonabant Benefits In addition, weight loss, Acomplia rimonabant is also beneficial for smoking cessation and cardiovascular disease / metabolic risks associated with obesity. Acomplia rimonabant's 2yrs clinical trials have reflected promising signs of averting weight regain after prior weight loss.

Rimonabant Pricelist

Please wait while we load the price list
Rimonabant will be made available to overweight or obese patients who cannot take, or who have had no success with, two other drugs, orlistat and sibutramine. It comes after concerns about rimonabant's side effects, including suicidal thoughts and depression. The Medicines and Healthcare Products Regulatory Agency said last month that it had received 720 reports of adverse drug reactions - totalling 2,123 individual reactions - in the UK since the drug was launched in 2006. But the National Institute for Clinical Excellence said: "Being overweight or obese can lead to a range of serious health problems, including heart disease, type-2 diabetes, osteoarthritis and some cancers." Copyright c 2008 Independent Newspapers UK Limited. All rights owned or operated by The Independent.

Abstract Introduction: Obesity and overweight affect over 1 billion people worldwide and are leading causes of morbidity and mortality. Clinical features of obesity converge with those of the metabolic syndrome and type 2 diabetes, greatly increasing the risk of long-term adverse outcomes. Aims: To review the evidence on rimonabant, a novel CB1 receptor antagonist, for the treatment of obese and overweight patients. Related Results Lancet, BMJ studies sound concern over anti-obesity drug rimonabantRimonabant improves cardiovascular risk profileRimonabant improves cardiovascular risk profileNew drug application for rimonabant pulledRimonabant enhanced weight loss success, improved lipids Evidence review: There is clear evidence that rimonabant 20 mg/day in conjunction with a hypocaloric diet causes a mean weight loss of 4.